Half of the participants took a semaglutide tablet daily and half took a placebo. Participants continued their assigned regimen for an average of just under four years. By the end of the trial ...

INDIANAPOLIS – The way people are accessing GLP-1 medications Semaglutide and Tirzepatide is going to become very limited after the drugs were taken off the FDA’s shortage list. Hundreds of ...